Abstract: The present invention relates to methods and kits for treating cardiovascular disease.

Abstract: The disclosure relates to compositions and methods for reducing the risk of developing a lung cancer, colorectal cancer, or metastatic breast cancer in a subject, and methods of treating the same, comprising identifying a subject who has one or more risk factors for lung, colorectal or metastatic breast cancer and carries IL-1 single nucleotide polymorphisms (SNPs) associated with high levels of inflammation.

Abstract: The present invention provides stratification methods and kits to identify whether an individual having an inflammation-related disorder has genotype-specific differential expression of IL-1, i.e., is a “high” or “low” producer of IL-1, such that s/he can be provided an appropriate anti-inflammatory drug and at an appropriate dose. The stratification of high or low IL-1 producers is used to guide assignment of different drug doses and therefore reduce drug toxicity and adverse events in an individual who, without stratification, may be prescribed a higher dose than needed to manage the primary indication. The use of IL-1 stratification of drug dosing would allow a better clinical benefit-risk appraisal in an individual patient.

Abstract: The present invention provides stratification methods and kits to identify whether an individual having an inflammation-related disorder has genotype-specific differential expression of IL-1, i.e., is a “high” or “low” producer of IL-1, such that s/he can be provided an appropriate anti-inflammatory drug and at an appropriate dose. The stratification of high or low IL-1 producers is used to guide assignment of different drug doses and therefore reduce drug toxicity and adverse events in an individual who, without stratification, may be prescribed a higher dose than needed to manage the primary indication. The use of IL-1 stratification of drug dosing would allow a better clinical benefit-risk appraisal in an individual patient.

Abstract: The present invention relates to methods and kits for treating cardiovascular disease.

Abstract: The present invention relates, in part, to methods and kits for treating cardiovascular disease.

Abstract: The present invention relates, in part, to methods and kits for treating cardiovascular disease.

Abstract: The present invention relates generally to methods for predicting progression, initiation and susceptibility of osteoarthritis in human subjects using their genotype test results.

Abstract: The present invention relates, in part, to methods and kits for treating cardiovascular disease.

Abstract: The present invention relates, in part, to methods and kits for treating cardiovascular disease.

Abstract: The present invention provides stratification methods and kits to identify whether an individual having an inflammation-related disorder has genotype-specific differential expression of IL-1, i.e., is a “high” or “low” producer of IL-1, such that s/he can be provided an appropriate anti-inflammatory drug and at an appropriate dose. The stratification of high or low IL-1 producers is used to guide assignment of different drug doses and therefore reduce drug toxicity and adverse events in an individual who, without stratification, may be prescribed a higher dose than needed to manage the primary indication. The use of IL-1 stratification of drug dosing would allow a better clinical benefit-risk appraisal in an individual patient.

Abstract: The present invention relates generally to methods for predicting progression, initiation and susceptibility of osteoarthritis in human subjects using their genotype test results.

Abstract: The kits and methods of the present invention relate to the diagnosis of cardiovascular disorders. In one aspect, the invention discloses a method and a kit for determining whether a subject has a fragile plaque disorder. In one aspect, the invention discloses a method and a kit for determining whether the subject has an occlusive disorder. In one aspect, the invention discloses a method and a kit for determining whether the subject has a restenosis disorder. Other methods of the present invention relate to the selection of therapeutics for a patient with a cardiovascular disease.

Abstract: Diagnostics and therapeutics for osteoporosis, which are bases upon the identification of a subjects IL-1 haplotype and genotype pattern are described.

Abstract: The methods of the present invention relate to the diagnosis of cardiovascular disorders. In one aspect, the specification discloses methods for determining a subject's predisposition to increased risk for myocardial infarction.

Abstract: Methods and kits for determining whether a subject has or is predisposed to developing restenosis are provided.

Abstract: Diagnostics and therapeutics for osteoporosis, which are bases upon the identification of a subjects IL-1 haplotype and genotype pattern are described.

Abstract: Certain aspects of the invention relate to methods for determining a subject's susceptibility to the early onset or progression of aging-related conditions. In certain aspects the invention relates to accessing the genotype of a subject with respect to an allele of IL-1 pattern 1, pattern 2 and/or pattern 3. In other aspects, the invention relates to methods for selecting a therapeutic regimen, identifying age-related biomarkers, monitoring the progress of age-related conditions and identifying therapeutics for delaying or diminishing the onset of aging-related conditions.

Abstract: Methods and kits for determining whether a subject has or is predisposed to developing a disease which is associated with IL-1 polymorphisms and assays for identifying therapeutics for treating and/or preventing the development of these diseases are provided.

Abstract: Methods and kits for determining whether a subject has or is predisposed to developing a disease which is associated with IL-1 polymorphisms and assays for identifying therapeutics for treating and/or preventing the development of these diseases are provided.